AZD1656

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glucose Lowering

Conditions

Glucose Lowering

Trial Timeline

Mar 1, 2010 → Oct 1, 2010

NCT ID

NCT01069926

About AZD1656

AZD1656 is a phase 1 stage product being developed by AstraZeneca for Glucose Lowering. The current trial status is completed. This product is registered under clinical trial identifier NCT01069926. Target conditions include Glucose Lowering.

What happened to similar drugs?

4 of 6 similar drugs in Glucose Lowering were approved

Approved (4) Terminated (3) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Candesartan + PlaceboAstraZenecaApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

❌UX007 + PlaceboUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01221519	Phase 1	Completed	Sep 1, 2010	Jan 1, 2011	Type 2 Diabetes Mellitus
NCT01069926	Phase 1	Completed	Mar 1, 2010	Oct 1, 2010	Glucose Lowering
NCT00819884	Phase 1	Completed	Jan 1, 2009	May 1, 2009	Type II Diabetes
NCT00741689	Phase 1	Completed	Aug 1, 2008	Dec 1, 2008	Healthy Volunteers

Competing Products

17 competing products in Glucose Lowering

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
Candesartan + Placebo	AstraZeneca	Approved	35
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg	Merck	Phase 2	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007	Ultragenyx Pharmaceutical	Phase 2	21
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 3	26
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	25
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25